NAD IV therapy: what the evidence actually shows

NAD IV therapy has become a status symbol — celebrities like Hailey Bieber and Kendall Jenner have put roughly $1,000 infusion sessions on the cultural map. The pitch is simple: NAD+ is central to how your mitochondria make energy, and levels decline with age, so topping up the molecule straight into a vein should slow aging and boost vitality. But as a new USA Today report lays out, the pitch is running far ahead of the proof.

Why did NAD IVs get so popular?

It started with real biology. Researchers discovered that NAD levels can decline or become dysregulated in certain tissues with age. Then studies in animals suggested that raising NAD might improve some aspects of metabolic health, age-related cellular function, and even physical performance. As the report notes, those mouse findings 'fostered the belief that raising NAD could slow or improve aging-related diseases, and perhaps even extend human lifespan' — and social media did the rest. Taking NAD orally is not useful because it is degraded in the intestine, so the market converged on the IV route, where an infusion can take an hour or longer because faster administration is difficult to tolerate.

What does the human evidence actually show?

'We still have no research that shows NAD extends lifespan in humans,' the report quotes. Animal studies cannot establish that NAD infusions provide the same benefits in people — and much of the animal work tested NAD precursors rather than intravenous NAD itself. The 2026 study most often in the background had only 14 participants and was designed to evaluate short-term safety and tolerability, not benefits. In short: the mechanism is real, the animal data is interesting, and the human evidence for anti-aging effects is not there.

What should you do with this information?

That does not mean the infusions are proven safe, either. The long-term safety profile is unsettled, and researchers note theoretical concerns linking sustained NAD elevation to altered cellular metabolism and potential oncogenic pathways. If you are considering one, treat it like any experimental intervention: ask what outcome has actually been measured in people, and talk to a clinician first — not an influencer.

Where the evidence stands

• Established: NAD+ is essential to mitochondrial energy metabolism, and its levels decline or become dysregulated in some tissues with age.
• Preliminary: NAD precursors raise NAD-related metabolites in short human studies; mouse studies show metabolic effects.
• Contested: Whether IV NAD improves energy, physical performance, or aging outcomes in people.
• Absent: No human trial shows NAD IV extends lifespan or treats aging; long-term safety data are lacking.